Skip to main content
NTLA logo

NTLA · Intellia Therapeutics, Inc. · Analyst Estimates

Track NTLA — free
$12.06 +0.00 (+0.00%)
Market Cap
$1.65B
Shares
140.13M
Volume · Sep 30 5.32M Avg daily vol (3M) 3.93M

Analyst Estimates

Compare analyst forecasts for Intellia Therapeutics, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.

Captured 2026-09-30 23:28 UTC · Publication dates shown per estimate · 16 metric / period groups

FY ending 2026-12-31

Analyst estimates for FY ending 2026-12-31
Metric Low Average High Analyst count Average, 30 days ago Average, 60 days ago Average, 7 days ago Average, 90 days ago Estimates lowered, last 30 days Estimates lowered, last 7 days Estimates raised, last 30 days Estimates raised, last 7 days
EPS
USD
Publication date not stated
-3.41
-3.15654
-2.83
—
-3.15092
-3.13446
-3.15654
-3.1706
— — — —
EPS
analysts
Publication date not stated
— — —
16
— — — —
7
7
8
8
Revenue
USD
Publication date not stated
22707000
51880430
100000000
— — — — — — — — —
Revenue
analysts
Publication date not stated
— — —
17
— — — — — — — —

FY ending 2027-12-31

Analyst estimates for FY ending 2027-12-31
Metric Low Average High Analyst count Average, 30 days ago Average, 60 days ago Average, 7 days ago Average, 90 days ago Estimates lowered, last 30 days Estimates lowered, last 7 days Estimates raised, last 30 days Estimates raised, last 7 days
EPS
USD
Publication date not stated
-3.62
-2.59903
0.97
—
-2.60278
-1.72743
-2.59903
-1.80099
— — — —
EPS
analysts
Publication date not stated
— — —
16
— — — —
10
10
5
5
Revenue
USD
Publication date not stated
8758000
126255330
685600000
— — — — — — — — —
Revenue
analysts
Publication date not stated
— — —
17
— — — — — — — —

Q ending 2026-09-30

Analyst estimates for Q ending 2026-09-30
Metric Low Average High Analyst count Average, 30 days ago Average, 60 days ago Average, 7 days ago Average, 90 days ago Estimates lowered, last 30 days Estimates lowered, last 7 days Estimates raised, last 30 days Estimates raised, last 7 days
EPS
USD
Publication date not stated
-0.89
-0.7887
-0.71
—
-0.7886
-0.77999
-0.78936
-0.7894
— — — —
EPS
analysts
Publication date not stated
— — —
15
— — — —
6
6
6
6
Revenue
USD
Publication date not stated
0
9767470
15000000
— — — — — — — — —
Revenue
analysts
Publication date not stated
— — —
15
— — — — — — — —

Q ending 2026-12-31

Analyst estimates for Q ending 2026-12-31
Metric Low Average High Analyst count Average, 30 days ago Average, 60 days ago Average, 7 days ago Average, 90 days ago Estimates lowered, last 30 days Estimates lowered, last 7 days Estimates raised, last 30 days Estimates raised, last 7 days
EPS
USD
Publication date not stated
-0.91
-0.76069
-0.41
—
-0.76788
-0.7657
-0.76136
-0.78477
— — — —
EPS
analysts
Publication date not stated
— — —
15
— — — —
5
5
7
7
Revenue
USD
Publication date not stated
0
17087350
69600000
— — — — — — — — —
Revenue
analysts
Publication date not stated
— — —
15
— — — — — — — —
Key facts CIK 1652130 CUSIP 45826J105 13F (30d) 11 filings 7 filers Visit website Investor relations